Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Antitumor effect of combining STING agonist (ADU-S100) and Doxorubicin versus Doxorubicin alone or control vehicle in mouse sarcoma cell line (WEHI-164)

ABSTRACT: Doxorubicin treatment induces the expression of proinflammatory cytokines through the activation of the STING pathway. Our study demonstrates that the combined administration of the STING agonist ADU-S100 significantly enhances the antitumor efficacy of doxorubicin in a syngeneic mouse model of sarcoma using the WEHI-164 cell line.

ORGANISM(S): Mus musculus

PROVIDER: GSE287710 | GEO | 2025/11/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Antitumor effect of combining STING agonist (ADU-S100) and Doxorubicin versus Doxorubicin alone or control vehicle in mouse sarcoma cell line (WEHI-164)

Project description:Antitumor effect of combining STING agonist (ADU-S100) and Doxorubicin versus Doxorubicin alone or control vehicle in mouse sarcoma cell line (WEHI-164)

| PRJNA1214272 | ENA

Gene expression profile at single cell level of a mesothelioma patient specimen treated with ADU-S100

Project description:STING agonists are in clinical development, yet their mechanisms of action remain unclear. We used single cell RNA sequencing (scRNA-seq) to analyze response to ADU-S100 in a mesothelioma patient specimen ex vivo.

2022-05-03 | GSE201925 | GEO

Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100 [II]

Project description:Two murine melanoma models (B16 and BPR) were treated with PBS or STING agonist ADU-S100 in vivo. Dose 1 was administered intratumorally on day 10, and a second dose was given on day 14. Tumors were collected 6 hours after the second dose and RNA was isolated. RNA was run on the Nanostring mouse PanCancer Immune Profiling Panel.

2023-12-09 | GSE249295 | GEO

Gene expression profiles of murine melanoma after treatment with STING agonist ADU-S100 [I]

Project description:Murine BPR melanomas were treated with either ADU-S100 or ADU-S100 + inhibitors of ARG2, COX2, and NOS2. Tumors were collected 7 days after treatment initiation and RNA was isolated and run on the Nanostring mouse Tumor 360 panel.

2023-12-09 | GSE249294 | GEO

Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100

Project description:Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100

| PRJNA1048456 | ENA

Gene expression profiles of murine melanoma after treatment with STING agonist ADU-S100 [I]

Project description:Gene expression profiles of murine melanoma after treatment with STING agonist ADU-S100 [I]

| PRJNA1048459 | ENA

Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100 [II]

Project description:Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100 [II]

| PRJNA1048461 | ENA

Single-cell RNA sequencing on TILs from 4T1 mouse model treated with STING agonist deliveredy by PEG biopsy marker shows activation of antigen presenting cells and macrophages but does not show T cell clonality.

Project description:To better characterize the TME effects of ADU-S100 delivered by the PEG, we performed single cell RNA sequencing (scRNA-seq) on CD45+ immune cells from 4T1 tumors 14 days after treatment. We found that antigen presenting cell (APC) and macrophage clusters exhibited robust upregulation of IFN-induced genes by ADU-S100, as well as significant enrichment for hallmark IFN gene signatures. To explore whether immune escape could be secondary to a failure of STING agonist to induce T-cell clonality and expansion, we further performed T-cell receptor sequencing (TCR-seq) on these CD45+ immune cells from animals treated with PEG markers with PBS or 100 µg ADU-S100. We then analyzed the frequency of unique clonotypes that were expanded following PBS versus ADU-S100 treatment. In both groups, there was no evidence for clonotype expansion.

2025-04-21 | GSE294854 | GEO

Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (WEHI-164)

Project description:WEHI-164 tumour samples taken after 75% debulking surgery, followed by treatment with poly(I:C) loaded hydrogel.

2023-06-04 | GSE230269 | GEO

Single-cell RNA sequencing on peripheral blood PBMCs from 4T1 mouse model treated with STING agonist deliveredy by PEG biopsy marker does not reveal peripheral T cell clonal expansion.

Project description:To explore whether immune escape could be secondary to a failure of STING agonist to induce T-cell clonality and expansion, we performed single-cell RNA sequencing (scRNAseq) and T-cell receptor sequencing (TCR-seq) on peripheral PBMCs from animals treated with PEG markers with PBS or 100 µg ADU-S100, using the low tumor burden model of 4T1. Cell types were clustered based on gene signature analysis with 9 resultant clusters. We then analyzed the frequency of unique clonotypes that were expanded following PBS versus ADU-S100 treatment. In both groups, most of the cells that had a unique clonotype did not expand, showing a frequency of 1. There were no specific clonotypes that had a frequency over 5, indicating that ADU-S100 treatment of 4T1 mice does not result in peripheral T cell clonal expansion.

2025-04-21 | GSE294846 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data